You are here
Home > Drugs > ARISTADA™

Indications and usage 

Initial U.S. Approval:  2015

INDICATIONS AND USAGE: ARISTADA is indicated for treatment of schizophrenia

Dosage and administration 

Drug UPDATES:  ARISTADA™-- aripiprazole lauroxil injection, suspension, extended release
[Drug information  /  PDF]    Click link for the latest monograph
Dosing
:  Click (+) next to Dosage and Administration section

How supplied

HOW SUPPLIED/STORAGE AND HANDLING:
ARISTADA extended-release injectable suspension is available in strengths of 441 mg in 1.6 mL, 662 mg in 2.4 mL, and 882 mg in 3.2 mL. The kit contains a 5-mL pre-filled syringe containing ARISTADA sterile aqueous suspension and safety needles.

The 441 mg strength kit (NDC 65757-401-03; light blue label) contains three safety needles; a 1-inch (25 mm) 21 gauge, a 1½-inch (38 mm) 20 gauge, and a 2-inch (50 mm) 20 gauge needle.
The 662 mg strength kit (NDC 65757-402-03; green label) contains two safety needles; a 1½-inch (38 mm) 20 gauge and a 2-inch (50 mm) 20 gauge needle.
The 882 mg strength kit (NDC 65757-403-03; burgundy label) contains two safety needles; a 1½-inch (38 mm) 20 gauge and a 2-inch (50 mm) 20 gauge needle.

Storage
Store at room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (between 59°F and 86°F).

Reference

RISTADA™-- aripiprazole lauroxil injection, suspension, extended release
[Drug information  /  PDF]    Click link for the latest monograph

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates.  A local search option of this data can be found here.

ARISTADA™

thpxl